Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients

ICI therapy has greatly improved patient outcomes in melanoma, but at the cost of immune-related adverse events (irAEs). Data on the chronicity of irAEs, especially in real-world settings, are currently limited. We performed a retrospective chart review of 161 adult patients with melanoma treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Justin, Kartolo, Adi, Yeung, Cynthia, Hopman, Wilma, Baetz, Tara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600354/
https://www.ncbi.nlm.nih.gov/pubmed/36290906
http://dx.doi.org/10.3390/curroncol29100629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600354/
https://www.ncbi.nlm.nih.gov/pubmed/36290906
http://dx.doi.org/10.3390/curroncol29100629

Ejemplares similares